Phased Large Awards for Comparative Effectiveness Research (PLACER) – Cycle 3 2022

 

On April 21, 2022, The Patient-Centered Outcomes Research Institute (PCORI) announced funding for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. Read the preliminary PCORI Funding Announcement (PFA), as well as the complete PFA for the same funding opportunity for Cycle 3 2021.

Funding Opportunity Details

This PFA invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. Investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs.

Funding

  • Total allocated for this PFA: Up to $40 million in total costs
  • Total direct funding: $10 million

Maximum project duration

  • Total project period of 6.5 years (Feasibility phase: 1.5 years; Full-scale study phase: 5 years)

Important dates

September 7, 2022 – Applications open
September 12, 2022 – Town Hall
October 4, 2022 – Letters of Intent due
October 25, 2022 – LOI status notification
January 10, 2023 – Application deadline
April 2023 – Merit review
July 2023 – Awards announced
October 2023 – Earliest start date

For more information or to request a brief consultation, please contact Leslie MacGregor, PCORI Funding Specialist: Leslie_MacGregor@hms.harvard.edu